114 related articles for article (PubMed ID: 11569941)
21. Is it time to test metformin in breast cancer clinical trials?
Cazzaniga M; Bonanni B; Guerrieri-Gonzaga A; Decensi A
Cancer Epidemiol Biomarkers Prev; 2009 Mar; 18(3):701-5. PubMed ID: 19240238
[TBL] [Abstract][Full Text] [Related]
22. Insulin detemir--a new basal insulin analog.
Goldman-Levine JD; Lee KW
Ann Pharmacother; 2005 Mar; 39(3):502-7. PubMed ID: 15657117
[TBL] [Abstract][Full Text] [Related]
23. CJC-1131. ConjuChem.
Giannoukakis N
Curr Opin Investig Drugs; 2003 Oct; 4(10):1245-9. PubMed ID: 14649218
[TBL] [Abstract][Full Text] [Related]
24. Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Choy M; Lam S
Cardiol Rev; 2007; 15(5):264-71. PubMed ID: 17700385
[TBL] [Abstract][Full Text] [Related]
25. [Glimepiride in daily practice].
Jasik M
Przegl Lek; 2003; 60(6):409-12. PubMed ID: 14974179
[TBL] [Abstract][Full Text] [Related]
26. Inhaled human insulin ((insulin human [rDNA origin]) Inhalation Powder) in diabetes mellitus.
Mathieu C
Expert Opin Drug Metab Toxicol; 2006 Oct; 2(5):779-91. PubMed ID: 17014394
[TBL] [Abstract][Full Text] [Related]
27. [Therapeutic renaissance. Biguanides in type-2 diabetes: metformin].
Neye H
Pharm Unserer Zeit; 2002; 31(3):264-70. PubMed ID: 12071123
[No Abstract] [Full Text] [Related]
28. Hypoglycemic pharmacological treatment of type 2 diabetes: targeting the endothelium.
Nathanson D; Nyström T
Mol Cell Endocrinol; 2009 Jan; 297(1-2):112-26. PubMed ID: 19038307
[TBL] [Abstract][Full Text] [Related]
29. NN-414. Novo Nordisk.
Choi JK
Curr Opin Investig Drugs; 2003 Apr; 4(4):455-8. PubMed ID: 12808887
[TBL] [Abstract][Full Text] [Related]
30. [2-year data of large clinical comparative studies. Type 2 diabetes: lasting metabolic control with pioglitazone].
MMW Fortschr Med; 2004 Jul; 146(29-30):48-9. PubMed ID: 15540563
[No Abstract] [Full Text] [Related]
31. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
32. Drug evaluation: K-111, an insulin-sensitizing peroxisome proliferator-activated receptor alpha agonist.
Drew BG; Calkin AC
Curr Opin Investig Drugs; 2007 Apr; 8(4):324-30. PubMed ID: 17458183
[TBL] [Abstract][Full Text] [Related]
33. [Diabetes mellitus and heart failure: epidemiology and therapy].
Pfister R; Erdmann E
Herz; 2008 Apr; 33(3):178-83. PubMed ID: 18568311
[TBL] [Abstract][Full Text] [Related]
34. The role of vildagliptin in the management of type 2 diabetes mellitus.
Kleppinger EL; Helms K
Ann Pharmacother; 2007 May; 41(5):824-32. PubMed ID: 17456545
[TBL] [Abstract][Full Text] [Related]
35. Insulin therapy for type 2 diabetes.
Pergallo-Dittko V
Diabetes Self Manag; 2003; 20(5):17, 21, 23-4. PubMed ID: 14679948
[No Abstract] [Full Text] [Related]
36. Sitagliptin/metformin (Janumet) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377
[No Abstract] [Full Text] [Related]
37. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
Patsouris D; Müller M; Kersten S
Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
[TBL] [Abstract][Full Text] [Related]
38. Molecule of the month. XOMA-052.
Drug News Perspect; 2009 Oct; 22(8):497. PubMed ID: 20016858
[No Abstract] [Full Text] [Related]
39. [Dihydroxybenzoquinones derivatives: orally-available insulin mimetics].
Tanaka J
Nihon Rinsho; 2002 Sep; 60 Suppl 9():522-7. PubMed ID: 12387045
[No Abstract] [Full Text] [Related]
40. An overview of salsalate as a potential antidiabetic therapy.
Desouza CV
Drugs Today (Barc); 2010 Nov; 46(11):847-53. PubMed ID: 21225023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
